Three‐year U.S. pharmacovigilance report of brodalumab

Brodalumab, an interleukin‐17 receptor A antagonist, is approved for treatment of moderate‐to‐severe plaque psoriasis in adults without response or with loss of response to other systemic therapies. In the United States, there is a boxed warning for brodalumab regarding suicidal ideation and behavio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebwohl, Mark, Leonardi, Craig, Armstrong, April, Rawnsley, Nicole, Alexander, Binu, Goehring, Earl, Kerdel, Francisco, Jacobson, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286594/
https://www.ncbi.nlm.nih.gov/pubmed/34418244
http://dx.doi.org/10.1111/dth.15105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286594/
https://www.ncbi.nlm.nih.gov/pubmed/34418244
http://dx.doi.org/10.1111/dth.15105

Ejemplares similares